| Connie Mcdonald-bell, | |
|
205 Sage Rd, Suite 201, Chapel Hill, NC 27514-6995 | |
| (919) 942-4166 | |
| (919) 942-8693 |
| Full Name | Connie Mcdonald-bell |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 205 Sage Rd, Chapel Hill, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083715650 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 956 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Connie Mcdonald-bell, 205 Sage Rd, Suite 201, Chapel Hill, NC 27514-6995 Ph: (919) 942-4166 | Connie Mcdonald-bell, 205 Sage Rd, Suite 201, Chapel Hill, NC 27514-6995 Ph: (919) 942-4166 |
News Archive
H. Lundbeck A/S (Lundbeck) and Merck, known outside the United States and Canada as MSD, today announced a commercialization agreement for SYCREST (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST in the European Union (EU), where it is already approved, at the beginning of 2011.
Women receive poorer heart attack treatment than men, even when rates of diagnosis are the same, according to new research funded by the British Heart Foundation (BHF) and published in the Journal of the American College of Cardiology.
The novel coronavirus pandemic forced many countries into lockdown, requiring people to stay at home to prevent the spread of the deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The dramatic change to life has left many people in distress, affecting psychological and emotional wellbeing.
CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), following the U.S. Food and Drug Administration's (FDA) acceptance of a revised clinical trial protocol.
› Verified 4 days ago
Mrs. Anne Z. Pendleton-white, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1829 E Franklin St, Bldg. # 600, Chapel Hill, NC 27514 Phone: 919-968-3456 Fax: 919-932-3456 | |
Ms. Hannah Elizabeth Fouts, M.ED., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 703 Highland Trl, Chapel Hill, NC 27516 Phone: 919-219-3014 | |
Mrs. Alison Louise Schenk, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1829 E Franklin St, Bldg # 600, Chapel Hill, NC 27514 Phone: 919-968-3456 Fax: 919-932-3456 | |
Mrs. Lindsay J Sturtz, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 500 Carolina Mdws, Chapel Hill, NC 27517 Phone: 919-370-7110 Fax: 919-932-4644 | |
Jianliang Zhang, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 201 Covington Dr, Chapel Hill, NC 27514 Phone: 919-699-0460 | |
Celicia Bri Benitez, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 101 Manning Dr, Chapel Hill, NC 27514 Phone: 984-974-5300 | |
Vanessa Loiselle Mccullough, M.S. CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 615 Greenwood Rd, Chapel Hill, NC 27514 Phone: 585-764-1430 |